Analysts Set Expectations for CLRB Q3 Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Equities researchers at Brookline Capital Markets raised their Q3 2026 EPS estimates for Cellectar Biosciences in a research note issued on Tuesday, November 10th. Brookline Capital Markets analyst K. Dolliver now forecasts that the biopharmaceutical company will post earnings of ($0.46) per share for the quarter, up from their prior estimate of ($0.50). The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($2.39) per share. Brookline Capital Markets also issued estimates for Cellectar Biosciences’ FY2027 earnings at ($2.35) EPS.

Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.10.

A number of other equities research analysts have also commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Thursday, October 15th. Wall Street Zen downgraded Cellectar Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Cellectar Biosciences Stock Down 0.8%

Shares of NASDAQ:CLRB opened at $1.21 on Thursday. Cellectar Biosciences has a 12-month low of $1.11 and a 12-month high of $4.70. The business has a fifty day simple moving average of $1.68 and a 200 day simple moving average of $2.54.

About Cellectar Biosciences

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics and oncology treatments. Its technology platform uses phospholipid ether compounds, which are designed to preferentially accumulate in cancer cells and other diseased tissues while limiting exposure to healthy tissue. The company’s leading product candidate is iopofosine I 131, also known as CLR 131, a small-molecule radiopharmaceutical being studied for the treatment of hematologic malignancies, including relapsed or refractory multiple myeloma and certain types of lymphoma.